Skip to main content
Equibles

AKUMS · Akums Drugs and Pharmaceuticals Limited

Use AKUMS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AKUMS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
741.05 INR -8.85 (-1.18%) At close · Nov 13
Rebalance outlook locked
Market Cap
116.64B INR
Shares
157.39M
Volume · Nov 13 130.41K Avg daily vol (3M) 302.16K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Investor day
Close741.05 INR Open745.00 INR Day738.75–754.95 INR 52W close414.05–823.30 INR Avg vol 30d267K Last earningsNov 3, 2026 DataAug 2024–Nov 2026

Latest documents

2026
Nov 3
Earnings call
Revenue rises 31.9%, EBITDA rises 106% in Q2 FY27

ACOM Drugs and Pharmaceuticals Limited reported consolidated revenue of 1342 crores, up 31.9% year-on-year, and EBITDA of 195 crores, up 106%, for the quarter ended 30th September, 2026, as CDMO volumes grew more than 20%.

5 source passages
I am Ankit Jain, and I head Investor Relations at ACOM Drugs and Pharmaceuticals Limited. Welcome, everyone, to ACOM's Q2 FY27 earnings call. I am pleased to present the financial highlights for the quarter, 30th September, 2026. Revenue on a consolidated basis stood at 1342 crores, an increase of 31.9% year-on-year. EBITDA for the quarter stood at a healthy 195 crores, a multi-fold increase of 106% year-on-year. The CDMO business achieved a volume growth of more than 20% on September MET basis, showcasing increasing penetration of our offering within the India pharma market. Open the document at this passage
All documents

Quarterly results

Revenue Net income Net loss
· 10.10B INR 651.82M INR '25 Q3 · 10.56B INR 1.48B INR '25 Q4 ▲0.5% 10.24B INR 634.75M INR '26 Q1 ▼1.5% 10.18B INR 407.83M INR '26 Q2 ▲14.8% 11.60B INR 663.17M INR '26 Q3 ▲9.7% 11.58B INR 846.13M INR '26 Q4 ▲13.9% 11.67B INR 1.00B INR '27 Q1 LATEST ▲31.9% 13.42B INR 1.13B INR '27 Q2

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Price context
position in its 52-week range
Range low 414.05 INR Now 741.05 INR · 80% Range high 823.30 INR
vs 200-day avg +20% vs 50-day avg -3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Performance

5D 20D 120D MTD YTD
XNSE:AKUMS +0.8% -1.2% +42.5% +1.3% +63.4%

Exchange listing

Market
XNSE
Ticker
AKUMS
ISIN
INE09XN01023
Security
Ordinary share
Trading currency
INR

Company

Website
https://www.akums.in/
Investor relations
https://www.akums.in/investors/disclosures-under-regulation-46-of-sebi-lodr/

Other listings of this company

Share classes and depositary receipts can have different prices and dividends.

Recent dividends

Ex-dividend dateAmount per share
2026-07-03 3.00 INR

Upcoming investor events

No upcoming investor events are listed for this company yet.

Earnings calls

  • Earnings call · Q2 2027 2026-11-03 Audio Transcript
    Earnings Call
  • Earnings call · Q1 2027 2026-08-10 Transcript
    Earnings Call for the Quarter Ended June 30, 2026
  • Earnings call · Q4 2026 2026-05-18 Audio Transcript
    Earnings Call
  • Conference · March 2026 2026-03-10
    Bharat Connect Conference on 10th March 2026